VTGN News and Press, VistaGen Therapeutics Inc. From 09/20/22

Goldie Hawn to lead discussion on supporting mental health around the globe with preeminent C-suite executives, politicians, nonprofit leaders and entrepreneurs on the importance of mental health Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming...

In healthy subjects, intranasal administration of PH94B activated nasal chemosensory cells, rapidly reduced sympathetic tone, and provided rapid self-reported calmness Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment lands...

Are Penny Stocks Worth Buying Right Now or Not? If you’re considering investing in penny stocks, you might be wondering if they’re worth it. While there’s no easy answer, there are a few things you should keep in mind before making a decision. Penny stocks a...

VistaGen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that its Chief Executive Offi...

Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that Chief Ex...

3 Penny Stocks to Add to Your Watchlist Right Now While finding the best penny stocks to buy can be tricky, there are plenty of ways to do just that. In 2022, the stock market has continued to move significantly in both directions, resulting in major gains for some and major losses for ...

This week, there are plenty of penny stocks to buy, and this article discusses some of the cheapest names on the block. It’s important to remember that just because something is considered “cheap” doesn’t necessarily mean it’s worth the risk. The opposite ...

VistaGen Therapeutics ( NASDAQ: VTGN ) on Thursday said an independent group of biostatisticians recommended continuing its second phase 3 trial evaluating its nasal spray PH94B for the treatment of anxiety in adults with social anxiety disorder. The interim analysis of da...

VistaGen (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced it will host a conference call and...

Independent biostatisticians recommend continuing PALISADE-2 without any changes after conducting interim analysis of 140 completed subjects Topline data for PALISADE-2 trial expected in the first half of 2023 Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the...